Since May, a rare and vaccine-resistant strain of Ebola called Bundibugyo has claimed more than 2,060 lives across the Democratic Republic of Congo and Uganda, becoming the second-deadliest outbreak of the virus in recorded history. The World Health Organisation warns that the epidemic is accelerating faster than any before it, outpacing the systems designed to contain it. With no approved vaccine and early symptoms mistaken for common illness, humanity finds itself once again in a familiar and humbling position — running to catch up with nature's indifference.
WHO warns rare Ebola strain could become deadliest ever as 2,000 die
Over 2,060 deaths confirmed across 4,500 cases in Democratic Republic of Congo and Uganda since May outbreak declaration.
We are chasing the virus, the virus is ahead of us.
Mark
Why is this particular strain so much more dangerous than previous Ebola outbreaks?
Mimi
It's not necessarily more dangerous in terms of how the virus itself works—the 45 percent fatality rate is serious but not unprecedented for Ebola. The danger is in the combination: a rare strain with no existing vaccine, spreading in a region where early misdiagnosis delayed recognition, and moving faster than health systems can respond.
Mark
The WHO director said it's moving faster than any previous outbreak. What does that actually mean on the ground?
Mimi
It means the number of new cases is doubling more quickly, the geographic spread is outpacing containment efforts, and by the time contact tracers identify someone exposed, that person may have already infected others. The virus is ahead of the response.
Mark
If Merck's Ervebo vaccine already exists, why can't they just use it immediately?
Mimi
Because it was designed for a different Ebola species. They're testing whether it offers cross-protection to Bundibugyo, but that's still an open question. And even if it works, production capacity is limited. You can't vaccinate millions of people with a vaccine that doesn't exist yet in sufficient quantity.
Mark
How long until a Bundibugyo-specific vaccine is actually available?
Mimi
Months, at minimum. The IAVI vaccine is furthest along, but it hasn't entered Phase three trials yet. In an outbreak moving this fast, months can mean thousands of additional deaths.
Mark
Is there anything else slowing the response?
Mimi
Yes—the initial misdiagnosis. When symptoms looked like flu or malaria, people didn't isolate, didn't seek Ebola-specific care, didn't alert contact tracers. By the time the outbreak was recognized for what it was, it had already spread. That head start is part of why the virus is ahead now.
Mark
What happens if the outbreak reaches a major city?
Mimi
That's the unspoken fear. So far, most cases are in areas where the WHO can still attempt community-led containment. But Ebola in an urban center with dense population and limited healthcare infrastructure would be catastrophic.
The Pulse
- The Bundibugyo strain, carrying a 45% fatality rate and no approved vaccine, has infected over 4,500 people and killed more than 2,060 since the outbreak was declared in May — numbers that are still climbing.
- Early misdiagnosis as flu or malaria gave the virus a critical head start, allowing it to cross into Uganda and embed itself in communities before health workers understood what they were fighting.
- WHO's Africa director described the situation plainly: 'We are chasing the virus, the virus is ahead of us' — a single sentence that captured the scale of institutional strain on the ground.
- A community-led containment strategy is now underway, focusing on rapid detection, healthcare access, and breaking transmission chains, but daily reports of 68 new cases and 50 deaths signal the effort has not yet turned the tide.
- The real hope lies in laboratories — Merck's Ervebo is being trialled for cross-protection, Oxford scientists are developing a Bundibugyo-specific vaccine, and at least four other research groups are racing to fill a gap that could define the outbreak's final toll.
Since May, a rare and vaccine-resistant strain of Ebola called Bundibugyo has claimed more than 2,060 lives across the Democratic Republic of Congo and Uganda, becoming the second-deadliest outbreak of the virus in recorded history. The World Health Organisation warns that the epidemic is accelerating faster than any before it, outpacing the systems designed to contain it. With no approved vaccine and early symptoms mistaken for common illness, humanity finds itself once again in a familiar and humbling position — running to catch up with nature's indifference.
In May, the Democratic Republic of Congo confirmed an Ebola outbreak caused by the Bundibugyo strain — a rare variant never before seen at this scale, and one for which no approved vaccine exists. By mid-August, more than 4,500 cases had been recorded across the country and into Uganda, with over 2,060 people dead. The WHO's director general warned that at its current pace, the outbreak would surpass the 2014–2016 West African epidemic, which killed more than 11,000 people and remains the deadliest on record.
The virus gained early ground through confusion. Its first symptoms — fever, headache, exhaustion, vomiting — were mistaken for flu or malaria, and by the time health workers identified Bundibugyo, it had already crossed borders. Uganda reported 20 confirmed cases and 2 deaths. Single daily reports from the DRC were recording 68 new infections and 50 deaths. The WHO's Africa director offered a blunt summary of the situation: the virus was ahead of them.
The response shifted toward community-led containment — early detection, rapid healthcare access, and support for overwhelmed medical workers. But the deeper race was unfolding in research labs. Merck's Ervebo, approved for a different Ebola species, entered a randomised trial to test whether it might offer cross-protection against Bundibugyo. Oxford scientists were developing a strain-specific vaccine using the same viral vector technology behind the Oxford-AstraZeneca Covid jab. At least three other research groups were working on alternatives, though none had yet reached human trials.
The arithmetic was unsparing: a virus spreading faster than any before it, a population with no immunity, and a vaccine supply that did not yet exist in meaningful quantities. What unfolded in the weeks ahead would determine whether the outbreak could be slowed — or whether it would become something the world had never seen before.
In May, the Democratic Republic of Congo confirmed what would become the second-largest Ebola outbreak in recorded history. By mid-August, more than 4,500 cases had been documented across the country and into Uganda, with over 2,060 people dead. The culprit was a rare strain called Bundibugyo—one that had never before driven an epidemic of this scale, and one for which no approved vaccine existed.
Tedros Ashanom Ghebreyesus, the director general of the World Health Organisation, stood before reporters in Geneva and delivered a stark assessment: the virus was moving faster than any Ebola outbreak before it. At its current trajectory, he said, it would surpass the West African epidemic of 2014-2016, which had killed more than 11,000 people and stood as the deadliest on record. This was the Democratic Republic of Congo's seventeenth Ebola outbreak, but the first caused by Bundibugyo, a strain with a fatality rate of 45 percent.
The speed of transmission had been aided, in part, by early confusion. When the first cases emerged, symptoms—fever, headache, exhaustion, vomiting, diarrhea—were mistaken for flu or malaria. By the time health workers recognized what they were actually facing, the virus had already begun to spread through communities and across borders. Uganda reported 20 confirmed cases and 2 deaths. The Democratic Republic of Congo alone was recording 68 new cases and 50 deaths in single daily reports.
Mohamed Janab, who directs the WHO's African operations, captured the grim reality in a single sentence: "We are chasing the virus, the virus is ahead of us." The organization's response pivoted toward what it called a community-led approach—early detection, rapid access to healthcare, support for overwhelmed medical workers, and the mobilization of resources to interrupt transmission chains. Ebola spreads through blood and bodily fluids, a fact that made containment both scientifically straightforward and logistically brutal.
But the real race was happening in laboratories. Merck's Ervebo vaccine, already approved for a different Ebola species, was being rushed into a trial to test whether it might offer some cross-protection against Bundibugyo. The WHO launched what it called the R & D blueprint programme, randomizing contacts of confirmed cases to receive either Ervebo or a placebo, with plans to add new vaccine candidates as they became available. Oxford scientists were developing a Bundibugyo-specific jab using the same viral vector technology that had produced the Oxford-AstraZeneca Covid vaccine. Three other research groups were also working on alternatives, though none had yet entered human trials.
The non-profit group IAVI was developing another Bundibugyo-specific vaccine based on the same platform as Ervebo, but production timelines remained uncertain—months away, at best, before enough doses would exist for a Phase three trial. The calculus was brutal: a virus spreading faster than any before it, a population with no immunity, and a vaccine supply that did not yet exist in meaningful quantities. What happened in the coming weeks would determine whether the outbreak could be slowed before it became something worse than anything the world had seen.
Notable Quotes
It's already the second-biggest Ebola epidemic on record, and it's moving faster than any previous Ebola outbreak. At its current pace, it's on track to eclipse the West African Ebola outbreak of 2014-2016.— Tedros Ashanom Ghebreyesus, WHO director general
We are chasing the virus, the virus is ahead of us.— Mohamed Janab, WHO African Region director
Want the full story?
Read the original at The daily Star ↗
Health & Medicine